Lithium-induced renal disease

Last revised by Daniel J Bell on 25 Sep 2024

Lithium-induced renal disease is characterized by a progressive decline in renal function secondary to lithium therapy. There is a risk of progression to end-stage renal disease (ESRD).

The probability of lithium-induced chronic nephropathy leading to chronic renal failure has a hazard ratio of 2.5% (95% CI 1.6-4) and is related to 4:

  • increasing age

  • duration of lithium therapy

This risk seems to persist even after lithium therapy is halted 4.

Patients present with signs and symptoms of slowly progressive chronic renal failure or diabetes insipidus.

It is biochemically evidenced by increasing serum creatinine and decreased creatinine clearance.  

The lithium salt causes direct injury to the renal tubules. Renal biopsy demonstrates tubular atrophy, glomerulosclerosis, chronic interstitial nephritis, and distal tubular dilatation with microcyst formation 1.

Unique imaging appearance of numerous uniform microcysts and punctate echogenic foci which may be cortical or medullary in origin 2,4. The kidneys are normal in size.

  • may show microcalcifications within the microcysts in the renal medulla and cortex

  • T2: abundance of microcysts as small hyperintense 1-2 mm round lesions distributed randomly in the renal medulla and cortex 3,4

The duration of lithium therapy increases the risk of progression to end-stage renal disease (ESRD), however, discontinuation of medication may not necessarily halt the progression to ESRD.

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.